The Marked Chart Wire · Health
CagriSema
Novo Nordisk reports 25 percent weight loss in CagriSema trial
A post hoc analysis of the Phase 3 REDEFINE 1 trial showed that early responders to Novo Nordisk's CagriSema achieved a mean weight loss of 25 percent.
